title: Novel patented SRC kinase inhibitor.
abstract: Src family of protein tyrosine kinases (SFKs) plays key roles in the regulation of signal transductions in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Src-targeted compounds were developed to block the cell proliferation signal transductions for cancer therapy. Src kinase domain inhibitors were designed, synthesized and evaluated as anticancer agents, while the patents applied at the same time. Great progress has been made in the Src kinase inhibitor area. Herein, some predominant patents about Src kinase inhibitors of the recent years are reviewed.
authors.affiliation: State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No. 345, Fenglin Rd., Shanghai 200032, People's Republic of China.
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Lu
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Liu
authors.forename: Xin
authors.initials: X
authors.lastname: Cao
authors.forename: Bing-Hua
authors.initials: BH
authors.lastname: Jiao
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000639:trends; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D019061:src-Family Kinases